These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 23024219)

  • 41. Fibroblast growth factor-23 is a strong predictor of insulin resistance among chronic kidney disease patients.
    Fayed A; El Nokeety MM; Heikal AA; Abdulazim DO; Naguib MM; Sharaf El Din UAA;
    Ren Fail; 2018 Nov; 40(1):226-230. PubMed ID: 29619868
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dietary habits and counseling focused on phosphate intake in hemodialysis patients with hyperphosphatemia.
    Cupisti A; D'Alessandro C; Baldi R; Barsotti G
    J Ren Nutr; 2004 Oct; 14(4):220-5. PubMed ID: 15483782
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum level of fibroblast growth factor 23 in maintenance renal transplant patients.
    Sánchez Fructuoso AI; Maestro ML; Pérez-Flores I; Valero R; Rafael S; Veganzones S; Calvo N; De la Orden V; De la Flor JC; Valga F; Vidaurreta M; Fernández-Pérez C; Barrientos A
    Nephrol Dial Transplant; 2012 Nov; 27(11):4227-35. PubMed ID: 23144073
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evidence in favor of a severely impaired net intestinal calcium absorption in patients with (early-stage) chronic kidney disease.
    Viaene L; Meijers BK; Vanrenterghem Y; Evenepoel P
    Am J Nephrol; 2012; 35(5):434-41. PubMed ID: 22538635
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice.
    Perwad F; Azam N; Zhang MY; Yamashita T; Tenenhouse HS; Portale AA
    Endocrinology; 2005 Dec; 146(12):5358-64. PubMed ID: 16123154
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acute effects of dietary phosphorus intake on markers of mineral metabolism in hemodialysis patients: post hoc analysis of a randomized crossover trial.
    Tsai WC; Wu HY; Chiu YL; Yang JY; Pai MF; Wu YR; Lin WY; Hung KY; Chien KL; Hsu SP; Peng YS
    Ren Fail; 2021 Dec; 43(1):141-148. PubMed ID: 33427559
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.
    Toussaint ND; Pedagogos E; Tan SJ; Badve SV; Hawley CM; Perkovic V; Elder GJ
    Nephrology (Carlton); 2012 Jul; 17(5):433-44. PubMed ID: 22574672
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction.
    Hindricks J; Ebert T; Bachmann A; Kralisch S; Lössner U; Kratzsch J; Stolzenburg JU; Dietel A; Beige J; Anders M; Bast I; Blüher M; Stumvoll M; Fasshauer M
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):918-24. PubMed ID: 24612017
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
    Lioufas N; Toussaint ND; Pedagogos E; Elder G; Badve SV; Pascoe E; Valks A; Hawley C;
    BMJ Open; 2019 Feb; 9(2):e024382. PubMed ID: 30796122
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients.
    Viaene L; Bammens B; Meijers BK; Vanrenterghem Y; Vanderschueren D; Evenepoel P
    Nephrol Dial Transplant; 2012 May; 27(5):2017-22. PubMed ID: 22025115
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dietary phosphorus and kidney disease.
    Uribarri J
    Ann N Y Acad Sci; 2013 Oct; 1301():11-9. PubMed ID: 23876096
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum phosphate modifies the vascular response to vitamin D receptor activation in chronic kidney disease (CKD) patients.
    Zoccali C; Torino C; Curatola G; Panuccio V; Tripepi R; Pizzini P; Versace M; Bolignano D; Cutrupi S; Ghiadoni L; Thadhani R; Tripepi G; Mallamaci F
    Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):581-589. PubMed ID: 27113290
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men.
    Burnett-Bowie SM; Mendoza N; Leder BZ
    Bone; 2007 Apr; 40(4):913-8. PubMed ID: 17157573
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional study.
    Yasin A; Liu D; Chau L; Madrenas J; Filler G
    BMC Nephrol; 2013 Feb; 14():39. PubMed ID: 23413976
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease.
    Houston J; Smith K; Isakova T; Sowden N; Wolf M; Gutiérrez OM
    J Ren Nutr; 2013 Jan; 23(1):12-20. PubMed ID: 22406119
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease?
    Peiskerová M; Kalousová M; Kratochvílová M; Dusilová-Sulková S; Uhrová J; Bandúr S; Malbohan IM; Zima T; Tesar V
    Kidney Blood Press Res; 2009; 32(4):276-83. PubMed ID: 19797911
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
    Ix JH; Isakova T; Larive B; Raphael KL; Raj DS; Cheung AK; Sprague SM; Fried LF; Gassman JJ; Middleton JP; Flessner MF; Block GA; Wolf M
    J Am Soc Nephrol; 2019 Jun; 30(6):1096-1108. PubMed ID: 31085679
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of interactions between proteinuria, activity of fibroblast growth factor 23 and serum phosphate on renal progression in patients with chronic kidney disease: a result from the KoreaN cohort study for Outcome in patients With Chronic Kidney Disease study.
    Kim H; Park J; Nam KH; Jhee JH; Yun HR; Park JT; Han SH; Chung W; Oh KH; Park SK; Kim SW; Kang SW; Choi KH; Ahn C; Yoo TH
    Nephrol Dial Transplant; 2020 Mar; 35(3):438-446. PubMed ID: 30615179
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Insulin resistance is associated with Fibroblast Growth Factor-23 in stage 3-5 chronic kidney disease patients.
    Garland JS; Holden RM; Ross R; Adams MA; Nolan RL; Hopman WM; Morton AR
    J Diabetes Complications; 2014; 28(1):61-5. PubMed ID: 24125760
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The relationship between FGF-23 and ghrelin levels in CKD patients: preliminary data.
    Ozturk S; Ozkan O; Efe M; Yazici H; Gursu M; Kaya AH; Cebeci E; Sumnu A; Karadag S; Poturoglu S; Kazancioglu R
    Minerva Urol Nefrol; 2016 Apr; 68(2):227-32. PubMed ID: 26125281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.